AmgenvsPacific Biosciences of California

AMGN and PACB stock compared: price, dividend, valuation and results, from SEC filings.

AMGN

Amgen Inc.

$457.93

Value $247B

-0.95%
AMGN's page

PACB

Pacific Biosciences of California, Inc.

$1.82

Value $550M

-1.09%
PACB's page

Amgen (AMGN) has a market value of $247B and Pacific Biosciences of California (PACB) $550M. Over the last year, with dividends, AMGN moved +39.7% and PACB +13.0%. Dividend yield: AMGN 2.17%, PACB none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    AMGN$247B

    PACB$550M

    AMGN is 449 times PACB

  • Revenue, 12 months

    AMGN$38.9B

    PACB$161M

    AMGN is 241 times PACB

  • Net income, 12 months

    AMGN$9.4B

    PACB-$131M

  • Operating margin

    AMGN32.4%

    PACB-81.3%

    113.7 points apart

  • ROIC

    AMGN16.2%

    PACB-16.3%

    32.5 points apart

  • P/E

    AMGN26.3

    PACB–

  • Dividend yield

    AMGN2.2%

    PACB0.0%

    2.2 points apart

  • 5-year return

    AMGN+158.3%

    PACB-93.5%

    251.8 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

AMGN+158.3%

PACB-93.5%

010020020222023202420252026
Returns by period
PeriodAMGNWith dividendsPACBWith dividends
1 year since November 14, 2025+39.7%Price +36.0%+13.0%Price +13.0%
3 years since November 17, 2023+87.3%+23.3% a yearPrice +72.5%-78.3%-39.9% a yearPrice -78.3%
5 years since November 16, 2021+158.3%+20.9% a yearPrice +123.0%-93.5%-42.1% a yearPrice -93.5%
10 years since November 17, 2016+315.7%+15.3% a yearPrice +210.8%-76.2%-13.4% a yearPrice -76.2%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

AMGNAmgenPACBPacific Biosciences of California

Valuation

AMGNPACB
Valuation
Price$457.93$1.82
Market value$247B$550M
Enterprise value (EV)$288B$993M
P/E26.3–
P/E, 5-year median23.0–
P/B17.2–
EV/EBIT22.8–
Free cash flow yield3.9%–

Results and growth

AMGNPACB
Results and growth
Revenue, 12 months$38.9B$161M
Net income, 12 months$9.4B-$131M
Free cash flow, 12 months$9.6B-$143M
Earnings per share, 12 months$17.25-$0.42
Revenue growth, year on year10.0%3.9%
Revenue growth a year, past+7.6%over 5 years+15.2%over 5 years
EPS growth a year, past+2.9%over 5 years–

Margins and returns on capital

AMGNPACB
Margins and returns on capital
Gross margin70.9%34.4%
Operating margin32.4%-81.3%
Net margin24.1%-81.3%
ROIC16.2%-16.3%
ROE87.8%–

Balance sheet

AMGNPACB
Balance sheet
Cash$13.2B$199M
Total debt$54.0B$705M
Net debt / EBITDA2.3–
Interest cover4.8×-17.2×

Dividends and buybacks

AMGNPACB
Dividends and buybacks
Dividend yield2.2%–
Dividend per share, 12 months$9.94–
Dividend growth a year, past+8.1%over 5 years–
Buyback yield––
Shareholder yield2.2%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: AMGN or PACB

Didn't find what you were looking for?

Ask us
Which is bigger, Amgen or Pacific Biosciences of California?

By market value, Amgen ($247B) is about 449.1 times Pacific Biosciences of California ($550M), at today's prices.

How did AMGN and PACB stock do over the last 10 years?

Since November 17, 2016, AMGN's price moved +210.8% and PACB's -76.2%. With dividends: AMGN +315.7% (+15.3% a year), PACB -76.2% (-13.4% a year). Past returns do not predict future ones.

Which pays the higher dividend, AMGN or PACB?

The dividend yield at today's price is 2.17% for Amgen and none for Pacific Biosciences of California. Over the last twelve months they paid $9.94 and – per share.

Which has the higher profit margins, Amgen or Pacific Biosciences of California?

Over the last twelve months, the net margin was 24.1% for Amgen and -81.3% for Pacific Biosciences of California, and the operating margin 32.4% and -81.3%. Revenue was $38.9B and $161M.

Which is the better investment, Amgen or Pacific Biosciences of California?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.